CYP19A1 and breast cancer: These characteristics are showcased in the study by Forcignanò et al.: 'Short-term monitoring of denosumab effect in breast cancer patients receiving aromatase inhibitors using radiofrequency echographic multi-spectrometry (REMS) technology on femoral neck' [19].